We continue to integrate reputational risk into our risk management processes to ensure that managers build it into their everyday thinking. Appropriate tools are available in the form of a shared risk management philosophy, principles and a framework that all managers can use to reflect on behaviours, assess risks and positively shape their decision-making.
We use our formal internal risk assessment processes, together with external benchmarking and stakeholder dialogue, to help us identify the opportunities and challenges associated with our corporate responsibility. The same cross-functional group that contributed to the full CR risk assessment in 2006, reviewed the CR risks register during 2007, based on their knowledge of the external and internal environments, and shifts in the expectations of the stakeholder groups they are in contact with. Externalisation and outsourcing continue to be high on our agenda as a result of this review.
Our CR Priority Action Plan (below) provides a framework for managing the identified issues in line with our core values, including defined objectives and, where possible, appropriate key performance indicators (KPIs). The Plan is reviewed annually to make sure that it continues to be relevant. Additionally, the CR risk register is the basis for defining relevant additional CR issues to cover in our reporting, but which fall outside of the Priority Action Plan.
In 2007, we conducted a project to review the possibility of applying the Global Reporting Initiative (GRI) guidelines to our reporting. A cross-functional team including HR, Compliance, SHE, Corporate Communications and Global CR reviewed the GRI indicators against a number criteria, such as their relevance to our CR approach and to the target audiences for our reporting. The review also helped to identify any gaps in our existing Priority Action Plan. The outcomes formed the basis of our decision to become a GRI B+ reporter. Please see the GRI Content Index for more information on where to find relevant GRI-related information.
Integration of CR into all activities | Objective | Action plan | KPI (where appropriate) |
|---|
| CR considerations are included in all relevant strategies and decisions. | Continue to integrate CR into personal
performance objectives.
Continue internal
communication of
policies, framework,
standards and
guidelines.
Continue local
implementation.
Continue integration
of CR into learning
and development
programmes.
Continue sampling
of employee
understanding
and opinion. | Two-yearly global
employee survey plus
regular 'Snapshot' surveys.
Number of leaders
involved in CR training. | 2007 Performance against KPI
2,364 leaders involved in CR training (490 in 2006).
More information >> |
Corporate governance and compliance | Objective | Action plan | KPI (where appropriate) |
|---|
Application of highest ethical standards in all dealing with stakeholders.
Ensure globally
consistent implementation of required CR standards across the AstraZeneca group of
companies. | Continue to communicate the
Code of Conduct
including the procedure for reporting concerns.
Continue development of audit processes
to include CR.
Continue global auditing.
Work with new members of the
AstraZeneca Group
to ensure that our CR expectations are understood. | Number of audits conducted including CR. | 2007 Performance against KPI
26 Internal Facility Audits conducted (18 in 2006).
New, strengthened governance and risk management structure implemented.
New Code of Conduct approved for distribution to all employees in the frist half of 2008.
More information >> |
Patient safety | Objective | Action plan | KPI (where appropriate) |
|---|
Ensure patient safety continues to be a
fundamental Company
consideration for all our medicines, throughout their life-cycles. | Continue to focus on drug safety throughout
discovery, development, launch and marketing of each of our products.
Continue to communicate to build understanding of the benefits and risks associated with all medicines. | Establishing KPIs
is difficult in this area,
where the safety of
any medicine has to
be evaluated in terms
of its benefit/risk profile. Our commitment to
minimising the risks
and maximising the
benefits of our medicines is integrated into everything we do. | | More infomation >> |
Sales and marketing | Objective | Action plan | KPI (where appropriate) |
|---|
Ensure high ethical standards of sales and marketing practice applied in all countries
of operation. | Continue training
of sales and
marketing staff.
Monitor and review
compliance. | Number of confirmed
breaches of external
regulations or codes. | 2007 Performance against KPI
32 breaches across 59 countries surveyed.
More information >> |
Access to medicines including diseases of the developing world | Objective | Action plan | KPI (where appropriate) |
|---|
Ensure access to medicines is considered when defining pricing and market access strategies for new brands.
In the developing world, apply our skills and experience to
helping to improve healthcare delivery in a
sustainable way. | Continue to communicate our
framework for considering access.
Continue to research a new treatment for
TB. Continue discussions with relevant external organisations regarding development and delivery.
Focus on helping to strengthen healthcare
capabilities in the developing world. | Candidate drug identified for development as a new TB treatment.
Target: not earlier
than 2010. | 2007 Performance
More information (access to medicines) >>
More information (diseases of the developing world) >> |
Animal research | Objective | Action plan | KPI (where appropriate) |
|---|
Use the minimum
number of animals to
achieve our scientific
objectives.
Maximise the use
of non-animal methods in drug discovery.
Enhance the welfare of those animals we have to use. | Maintain annual site improvement plans covering animal welfare and the replacement,
reduction and refinement (3Rs)
of animal use at all AstraZeneca sites using animals.
Formal programme of animal welfare inspections of sites where studies are conducted by, or on behalf of, AstraZeneca. | Number of animals
used.
Percentage of sites with approved improvement plans (target 100%).
Percentage of sites
demonstrating positive
progress against their
improvement plans
(target 100%).
Percentage of scheduled
internal peer review
inspections completed
(target 100%).
Percentage of planned
external contractor
inspections completed
(target 100%). | 2007 Performance against KPI
Approx. 271,000 used in-house and approx. 13,500 used by external contractors.
100% sites with approved plans.
100% sites demonstrating positive progress.
100% of scheduled internal inspections completed.
91% of planned external contractor inspections completed.
More information >> |
Clinical trials| Objective | Action plan | KPI (where appropriate) |
|---|
Ensure that our clinical trial programmes continue to be safe,
well-designed and appropriate wherever they take place.
Open communication
of appropriate data. | Maintain consistent
ethical standards
worldwide, in line with our global policy.
Continue to update our public global clinical
trials website with latest information. | Percentage of ongoing
hypothesis-driven
clinical trials disclosed
through AstraZeneca’s
website and the US
National Library of
Medicine’s website.
Percentage of
disclosed data on
hypothesis-driven
global clinical trials
of all major products. | 2007 Performance against KPI
100%
100%
More information >> |
Human rights, including diversity | Objective | Action plan | KPI (where appropriate) |
|---|
Ensure we consistently live up to our core
values and our commitment to the principles of the UN
Declaration of Human Rights worldwide. Ensure diversity and inclusion are appropriately supported in our global workforce, reflected in
our leadership, and integrated into business and people
strategies. | Continue to roll
out common
Human Resources
Information System.
Establish global
KPI based on the
planned areas
of data collection. Build diversity and inclusion into business
performance management.
Focus on minimum
standards in talent
management, staffing, performance review and reward, and learning and development. | Percentage of women
at senior levels. | 2007 Performance against KPI
26% of 81 managers reporting to the Senior Executive Team are women
More information >> |
Driver safety | Objective | Action plan | KPI (where appropriate) |
|---|
Promote the safety of all those who drive
on Company business. | Continue to implement driver safety programmes worldwide with a particular focus on areas of greatest
driving activity. | Number of accidents
per million kilometres
driven by marketing
company employees. | 2007 Performance against KPI
Ongoing implementationon a country-specific basis.
More information >> |
Climate change | Objective | Action plan | KPI (where appropriate) |
|---|
| Minimise the impact of our business activities worldwide. | Our target is to ensure that our emissions from all sources in 2010, including releases from the use of pMDI products, will be no greater than they were in 2000 and 40% less than they were in 1990.
Make further substantial efforts to produce by 2010 an absolute
reduction of 12% in global warming emissions from all sources other than pMDIs, when compared to 2005. | Total emissions of
greenhouse gases from all sources including products in use.
Total emissions of
greenhouse gases
from all sources other
than pMDIs. | 2007 Performance against KPI
Total GWP (inc. products in use.) 1.29 million tonnes (1.31 in 2006)
Total GWP (other than pMDIs.) 0.95 million tonnes (0.96 in 2006).
More information >> |
Pharmaceuticals in the environment | Objective | Action plan | KPI (where appropriate) |
|---|
Continue to refine our
understanding of how products interact with
the environment and pursue opportunities
to reduce or eliminate
potential adverse
impacts. | Continue to work both independently and in collaboration with other
organisations to advance research.
Pursue site-specific opportunities to minimise the amount of product lost to waste water during manufacturing activities.
Improve the integration of environmental information into the
drug development process.
Make environmental risk data on our new products, together with available information on our existing products, publicly available via the Swedish Doctors Prescribing Guide, FASS.se website using the voluntary disclosure system introduced by the Swedish pharmaceutical trade association (LIF).
| All information, as recommended by LIF, will be submitted to FASS.se in line with the timetable set by LIF, which has a target date for the completion of a full review by end of 2010.
| 2007 Performance against KPI
100% of available data, as recommended by LIF, was published. This included publication of environmental data for 5 substances during 2007. A total of 27 AstraZeneca substances with environmental data are now included in the database. More information >> |
Suppliers | Objective | Action plan | KPI (where appropriate) |
|---|
Encourage our suppliers to embrace CR standards similar
to our own and work with them to share best practice and help them to improve, if appropriate. | Continue to include
CR in our global
purchasing category
management
processes.
Implementation of
the CR in Purchasing
Guideline in countries
where we have
major marketing,
manufacturing or
research activities.*
Continue the rolling
programme of audits
of chemical intermediate and
active pharmaceutical
ingredient suppliers.
Broaden the scope
to include formulation
and packaging
suppliers. | Continue to reference
CR in all category plans.
CR referenced in all new contracts and master agreements generated from the countries in
scope.*
Number of audits.
* Including UK, US,
Sweden, Japan, China, India, Canada, Mexico
and Puerto Rico. | 2007 Performance against KPI
CR being included in the roll-out of our new category management processes.
CR included in all new contracts and master agreements generated in the countries in scope. *
Supplier evaluation procedure updated.
33 audits of manufacturing facilities at 29 different suppliers conducted (17 in 2006).
More information >> |
The content of this page was externally assured by BureauVeritas, February 2008 |